NCT07283848 2025-12-26
Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma
Massachusetts General Hospital
Phase 2 Withdrawn
Clinical Trials
15 trialsNCT04180761 2025-04-03
ProPeC
University Hospital Tuebingen
Phase 2 Withdrawn
NCT04863430 2025-02-21
Apatinib with Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma of the Stomach
Peking University
Phase 2 Withdrawn
NCT05703555 2024-02-28
INTRUSION
Erasmus Medical Center
Phase 2 Withdrawn
NCT05411679 2023-06-12
EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer
Ellipses Pharma
Phase 2 Withdrawn
NCT03554395 2020-10-19
Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Gastric Cancer
Fuda Cancer Hospital, Guangzhou
Phase 2 Withdrawn
NCT03704077 2020-05-19
An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Bristol-Myers Squibb
Phase 2 Withdrawn
NCT03766607 2019-09-19
Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer
Korean South West Oncology Group
Phase 2 Withdrawn
NCT00387530 2019-08-02
Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Cancer
University of California, San Diego
Phase 2 Withdrawn
NCT02943603 2018-07-13
A Study of Perioperative mFOLFOX6 Plus Pembrolizumab in Patients With Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) and Stomach
University of Pittsburgh
Phase 2 Withdrawn
NCT00800969 2016-06-23
Prospective Evaluation of the Preoperative Lymph Node Staging in Patients With Cancer of the Esophagogastric Junction and Stomach
University of Zurich
Phase 2 Withdrawn
NCT01252108 2015-11-17
Evaluation of SQ109 Plus PPI in Urea Breath Test-Positive Volunteers
Sequella, Inc.
Phase 2 Withdrawn
NCT00620607 2015-08-26
huC242-DM4 Treating Patients With Metastatic Gastric or Gastroesophageal Junction Carcinomas
ImmunoGen, Inc.
Phase 2 Withdrawn
NCT01070290 2014-01-07
A Study of ARQ 197 Versus Investigator's Choice of Second-Line Chemotherapy in Patients With Locally Advanced or Metastatic Gastric Cancer Who Have Progressive Neoplastic Disease Following Treatment With One Prior Chemotherapy Regimen
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 2 Withdrawn
NCT00824811 2012-08-02
Topical Cyclosporine vs. Placebo for Epiphora Associated With Docetaxel
M.D. Anderson Cancer Center
Phase 2 Withdrawn